Relationship between clinical features and gene mutations in non-small cell lung cancer with osteoblastic bone metastasis.

Published on Jan 1, 2021in Cancer treatment and research
· DOI :10.1016/J.CTARC.2021.100440
Yutaka Takahara2
Estimated H-index: 2
(Kanazawa Medical University),
Keisuke Nakase1
Estimated H-index: 1
(Kanazawa Medical University)
+ 4 AuthorsShiro Mizuno22
Estimated H-index: 22
(Kanazawa Medical University)
Source
Abstract
Objective null Lung cancer patients presenting with osteoblastic bone metastases at the first visit is rare. We investigated the clinical characteristics and gene mutation rate of non-small cell lung cancer patients with osteoblastic bone metastases at the time of the initial diagnosis. null Materials and methods null We retrospectively screened newly diagnosed non-small cell lung cancer patients with osteoblastic bone metastases who presented from June 2015 to March 2021, and analyzed their clinical characteristics and status of EGFR gene mutations, EML4-ALK translocation and ROS1 rearrangements. For comparison, we collected data from patients with non-small cell lung cancer who had osteolytic bone metastases at their first visit between June 2015 and March 2021. null Results null Fifty patients had bone metastases at the initial diagnosis. Among them, eight patients (8/50 = 16%) had osteoblastic bone metastases, and the lung tumors in all of them were histopathologically adenocarcinomas. Among the eight cases, two were EGFR mutation-positive, none were EML4-ALK translocation-positive, two were ROS1 rearrangement-positive, and the remaining four cases were negative for all three gene mutations/rearrangements. Compared with the osteolytic bone metastasis group, the percentage of non-smokers was higher (p = 0.020) and the ROS1 rearrangement positivity rate was higher (p = 0.05) in the osteoblastic bone metastasis group. null Conclusion null Our results indicate that osteoblastic bone metastases in NSCLC are suggestive of adenocarcinoma, and that a high proportion of these patients might be positive for ROS1 rearrangements, and hence, indicated for more aggressive diagnostic biopsies.
📖 Papers frequently viewed together
4 Citations
References22
Newest
#1Xiao-Tian Wu (Fudan University)H-Index: 4
#2Jian-Wei Zhou (Fudan University)
Last. Ting Ge (Fudan University)
view all 4 authors...
ObjectiveTo investigate the clinical features and evaluate the prognostic factors in patients with bone metastases from non-small cell lung cancer (NSCLC).MethodsWe retrospectively investigated 356...
1 CitationsSource
#1Subba R. Digumarthy (Harvard University)H-Index: 38
#2Dexter P. Mendoza (Harvard University)H-Index: 9
Last. Justin F. Gainor (Harvard University)H-Index: 58
view all 9 authors...
Rearranged during transfection proto-oncogene (RET) fusions represent a potentially targetable oncogenic driver in non-small cell lung cancer (NSCLC). Imaging features and metastatic patterns of advanced RET fusion-positive (RET+) NSCLC are not well established. Our goal was to compare the imaging features and patterns of metastases in RET+, ALK+ and ROS1+ NSCLC. Patients with RET+, ALK+, or ROS1+ NSCLC seen at our institution between January 2014 and December 2018 with available pre-treatment i...
9 CitationsSource
#1Subba R. Digumarthy (Harvard University)H-Index: 38
#2Dexter P. Mendoza (Harvard University)H-Index: 9
Last. Alice T. Shaw (Harvard University)H-Index: 91
view all 10 authors...
Abstract Background ROS proto-oncogene 1 (ROS1) rearrangements are a known molecular target in non-small cell lung cancer (NSCLC). Our goal was to determine if ROS1-rearranged NSCLC has imaging features and patterns of metastasis, which differ from those of anaplastic lymphoma kinase (ALK)-rearranged or epidermal growth factor receptor (EGFR)-mutant NSCLC. Methods We retrospectively identified patients with metastatic ROS1-rearranged, ALK-rearranged, or EGFR-mutant NSCLC between January 2014 and...
16 CitationsSource
#1Yutaka Takahara (Kanazawa Medical University)H-Index: 2
#2Kouichi Yamamura (Kanazawa Medical University)
Last. Shiro Mizuno (Kanazawa Medical University)H-Index: 22
view all 15 authors...
Abstract A 53-year-old woman was referred to our hospital for detailed examination of abnormal chest shadows recognized on CT imaging. Transbronchial lung biopsy of a right S6 nodular shadow led to a diagnosis of lung adenocarcinoma. FDG-PET-CT showed FDG accumulation in the Th11 and L2 vertebral bodies and osteoblastic bone lesions. Since osteoblastic bone metastasis in lung cancer is extremely rare, CT-guided bone biopsy was performed. The tumor was diagnosed as ROS1-rearranged lung adenocarci...
1 CitationsSource
Liquid biopsy has been introduced as a new diagnostic concept predicated on the analysis of circulating tumour cells (CTCs) or circulating tumour-derived factors, in particular, cell-free tumour DNA (ctDNA). Highly sensitive liquid biopsy assays have been developed that can now be applied to detect and characterize minimal residual disease (MRD), which reflects the presence of tumour cells disseminated from the primary lesion to distant organs in patients who lack any clinical or radiological si...
298 CitationsSource
#1Ryan B. Corcoran (Harvard University)H-Index: 42
#2Bruce A. Chabner (Harvard University)H-Index: 99
Emerging Roles of Cell-free Tumor DNA in Oncology The capacity to detect new cancers, treatment-resistant variants, and tumor heterogeneity by noninvasive technology on the basis of tumor DNA in th...
285 CitationsSource
#1Riyadh Ali Mohammed Hammamy (Hamad Medical Corporation)H-Index: 1
#2Khalid Farooqui (Hamad Medical Corporation)H-Index: 1
Last. Wisam Ghadban (Hamad Medical Corporation)H-Index: 4
view all 3 authors...
Pulmonary adenocarcinoma is one of the major types of lung cancers in which metastasis is very common and it accounts approximately to one-third of all primary pulmonary cancers. Although a minority of patients with lung cancer are asymptomatic, which gets usually detected in routine chest radiography, most of the patients present with some symptoms. Lung cancer metastasis may occur virtually in every organ system. Patients with non-small-cell lung cancer commonly have extrathoracic metastases t...
7 CitationsSource
#1Mark Esposito (Princeton University)H-Index: 9
#2Theresa A. Guise (IU: Indiana University)H-Index: 67
Last. Yibin Kang (Princeton University)H-Index: 82
view all 3 authors...
: Bone metastasis, or the development of secondary tumors within the bone of cancer patients, is a debilitating and incurable disease. Despite its morbidity, the biology of bone metastasis represents one of the most complex and intriguing of all oncogenic processes. This complexity derives from the intricately organized bone microenvironment in which the various stages of hematopoiesis, osteogenesis, and osteolysis are jointly regulated but spatially restricted. Disseminated tumor cells (DTCs) f...
61 CitationsSource
#1Jonathan C. M. WanH-Index: 7
#2Charles E MassieH-Index: 33
Last. Nitzan RosenfeldH-Index: 41
view all 9 authors...
Circulating tumour DNA (ctDNA) analysis has the potential to improve prognostication, molecular profiling and disease monitoring in patients with cancer. This Review summarizes recent advances, potential applications in cancer research and personalized oncology, and the introduction of ctDNA into clinical use.
1,027 CitationsSource
#1Giulia Siravegna (UNITO: University of Turin)H-Index: 33
#2Silvia MarsoniH-Index: 43
Last. Alberto Bardelli (UNITO: University of Turin)H-Index: 102
view all 4 authors...
Analysis of circulating tumour components using liquid biopsy approaches holds considerable promise to improve the detection and treatment of cancer. In this Review, Alberto Bardelli and colleagues outline how different forms of liquid biopsy, and particularly the assessment of circulating tumour DNA, can be exploited to guide patient care, and discuss the progress made to date in integrating such analyses into the clinic.
839 CitationsSource
Cited By0
Newest